Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Unknown

CTS2190 Phase I /II Clinical Study in Patients

A Multi-center, Open-label, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS2190 in Patients With Solid Tumors

Outcome
Outcome unknown
Phase
Phase 1 / Phase 2
Status
Unknown
Study type
Interventional
Start
26 June 2023
Listed end
31 October 2025
Enrollment
224 participants
Sites
2
Primary outcomes
Dose Escalation:The maximum tolerated dose (MTD); Dose Escalation:The recommended phase 2 dose (RP2D); Dose Expansion:Objective response rate(ORR)
Sponsor type
Industry
Results posted
No
Last update
23 August 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.

Detailed description public domain (ClinicalTrials.gov)

This is a Phase 1/2 multi-center, open label study in solid tumor patients. Phase 1(Part1) is a dose escalation study of oral CTS2190 in patients with solid tumors,which is planned to treat up to 144 participants. Phase 2(Part2) is an open label, dose expansion study in specific tumor types. In both parts of the study, participants who tolerate the drug may continue the treatment until disease progression. The study duration for each subject is defined as beginning from 28 days prior to the first dose, until the subject withdrawal of informed consent, end of treatment, loss to follow-up or death, completes 48 weeks of continuous treatment or the study ends early, whichever occurs first. The end of study is defined as the date when the last subject completes the last visit specified in the protocol.